Lung Cancer Clinical Trials


Clinical trials play an important role in lung cancer treatment. After a promising new drug or therapy is identified and extensively tested to ensure its safety, clinical trials are conducted to determine its effectiveness in relation to the other treatments that are currently available. All emerging treatments go through this process; even the treatments that are now considered the “gold standard” in cancer care were once only available through clinical trials.

At Moffitt Cancer Center, we have a robust program that focuses exclusively on lung cancer clinical trials. Our trials explore treatments such as:

Our Lung Cancer Program has an extensive team of clinical trial coordinators, research data specialists and other medical professionals.
  • Chemotherapy drugs and combinations
  • Immunotherapy
  • Gene therapy
  • Targeted therapy

Clinical trials are a large part of what we do at Moffitt Cancer Center.

Through our efforts, we’ve compiled one of the largest existing outcomes databases in the nation, which contains more than 13 years of trial results.

Moffitt’s lung cancer research program has been awarded multiple grants by the National Cancer Institute. We have also been named a Comprehensive Cancer Center due to our ability to apply the findings of our research to our patients’ individualized treatment plans. At Moffitt, our trials don’t just benefit the patients who participate; they benefit every future patient whose lives are impacted by lung cancer.

Medically reviewed by Dr. Andreas Saltos.

To learn more about the available lung cancer clinical trials at Moffitt Cancer Center, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form. We don’t require a referral for consultation, and we’ll help you determine if you qualify for one of our trials.

 

calledFromCancerPage=True - substr=lung
testProtocol=

Open Clinical Trials:

Showing of 50

CLINICAL TRIAL 17431

A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine

Disease Site: Colon, Liver, Lung, Other Endocrine System, Pancreas, Small Intestine, Stomach

View Trial Details

CLINICAL TRIAL 17970

A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 19327

A Phase 2 Trial of Pembrolizumab Plus Bevacizumab in Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases

Disease Site: Non small cell lung cancer, Brain and Nervous System, Lung, Melanoma, skin, Gliomas

View Trial Details

CLINICAL TRIAL 19387

A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 19389

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-61186372, a Human Bispecific EGFR and cMet Antibody, in Subjects with Advanced Non-Small Cell Lung Cancer

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 19656

Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 19776

A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3021 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Disease Site: Any Site, Bones and Joints, Breast, Esophagus, Larynx, Lung, Other Respiratory and Intrathoracic Organs, Soft Tissue

View Trial Details

CLINICAL TRIAL 19940

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients with Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium BTCRC-LUN17-127

Disease Site: Small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 19942

Sequential Maintenance with Thoracic Radiotherapy and Durvalumab (MEDI4736) monotherapy or Durvalumab (MEDI 4736) combinations (Tremelimumab or Olaparib) in patients with Extensive Stage-Small Cell Lung Cancer after first line Platinum-based Chemotherapy

Disease Site: Lung, Small cell lung cancer

View Trial Details

CLINICAL TRIAL 19948

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1/PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

Disease Site: Non small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 20026

A Phase I Study of NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD1 Therapy

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20089

A Phase 1b, Multicenter, Two-Part, Open label Study Of Trastuzumab Deruxtecan, An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC)

Disease Site: Breast, Lung

View Trial Details

CLINICAL TRIAL 20163

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non©\Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature©\driven Analysis

Disease Site: Non small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 20178

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC

Disease Site: Non small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 20270

A Phase 2, Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-144 or LN-145) in Patients with Solid Tumors (IOV-COM-202)

Disease Site: Lung, Melanoma, skin, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20364

A Phase 1/2 Study of REGN5093 in Patients with Met-Altered Advanced Non-Small Cell Lung Cancer

Disease Site: Non small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 20373

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-Squamous NSCLC Patients who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Disease Site: Non small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 20409

A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 Mutation

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20520

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20530

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20579

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20712

A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV- Associated Solid Tumors, with Expansion Cohorts in HIV-Associated Solid tumors and a Cohort of HIV- Associated Classical Hodgkin Lymphoma

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20720

S1827, MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Disease Site: Small cell lung cancer, Lung

View Trial Details

CLINICAL TRIAL 20722

Phase III Randomized Trial of Pleurectomy/Decortication plus Chemotherapy with or without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) for Malignant Pleural Mesothelioma (MPM)

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20767

Integration of Immunotherapy into Adjuvant Therapy For Resected NSCLC: Alchemist Chemo-IO

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20826

S1701, A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20827

An Open-Label, Multi-Center Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20909

An Open-label Phase 1/1b Study to Evaluate the Safety and Pharmacokinetics of JNJ-73841937 (Lazertinib), a Third Generation EGFR-TKI, as Monotherapy or in Combinations With JNJ-61186372, a Human Bispecific EGFR and cMet Antibody in Participants with Advanced Non-Small Cell Lung Cancer

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20936

DuRvalumab (MEDI4736) with ChEmotherapy as First Line TreAtment in Advanced Pleural Mesothelioma - A Phase 3 Randomised Trial

Disease Site: Lung, Mesothelioma

View Trial Details

CLINICAL TRIAL 20938

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-Small Cell Lung Cancer (NSCLC) with Primary Tumors Between 1-4 cm

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20939

A Phase 1b/2 Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants with Non-Small Cell Lung Cancer (NSCLC)

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 20956

A Two-Part, Phase 1a/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, Safety and Efficacy Of PF-07284890 (ARRY-461) In Participants With BRAF V600-Mutant Solid Tumors With And Without Brain Involvement

Disease Site: Any Site, Brain and Nervous System, Larynx, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Other Skin, Brain metastasis, Gliomas

View Trial Details

CLINICAL TRIAL 20964

A Phase 2 Basket Study of Tucatinib in Combination with Trastuzumab in Subjects with Previously Treated, Locally-Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations

Disease Site: Brain and Nervous System, Breast, Ill-Defined Sites, Lung, Other Digestive Organ, Urinary Bladder, Brain metastasis, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 21022

A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN sotorasib) in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation

Disease Site: Any Site, Brain and Nervous System, Lung, Pancreas, Rectum, Brain metastasis, Leptomeningeal (LMD)

View Trial Details

CLINICAL TRIAL 21027

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Metastatic Non-Small-Cell Lung Cancer

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 21028

A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 21074

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFRMutant cfDNA in Plasma After Initiation of Osimertinib

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 21080

A Phase 1, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SRK-181 Administered Alone or in Combination with a Checkpoint Inhibitor in Patients with Locally Advanced or Metastatic Solid Tumors (DRAGON)

Disease Site: Any Site, Lung, Melanoma, skin, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21157

A Phase I/Ib Open-Label, Multi-Center, Dose-Escalation Study To Investigate The Safety, Pharmacokinetics And Preliminary Efficacy Of Intravenous NBF-006 In Patients With Non-Small Cell Lung, Pancreatic, Or Colorectal Cancer Followed By A Dose Expansion Study In Patients With KRAS-Mutated Non-Small Cell Lung Cancer

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 21163

A Phase 1/2 Study of Regn7075 (Egfrxcd28 Costimulatory Bispecific Antibody) in Combination with Cemiplimab in Patients with Advanced Solid Tumors

Disease Site: Anus, Breast, Cervix, Colon, Esophagus, Kidney, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Other Female Genital, Other Male Genital, Other Skin, Other Urinary, Pancreas, Prostate, Stomach

View Trial Details

CLINICAL TRIAL 21180

A First-in-Human, Two-Part, Open-Label, Clinical Study to Assess the Safety, Tolerability and Activity of Intravenous Doses of ICT01 as Monotherapy and in Combination with an Immune Checkpoint Inhibitor, in Patients with Advanced-Stage, Relapsed/Refractory Cancer (EVICTION Study)

Disease Site: Any Site, Breast, Colon, Larynx, Leukemia, other, Lip, Oral Cavity and Pharynx, Lung, Melanoma, skin, Ovary, Prostate, Stomach, Urinary Bladder

View Trial Details

CLINICAL TRIAL 21222

Older Non-Small Cell Lung Cancer Patients (>/= 70 Years of Age) Treated With First-Line Mk-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist s/Patient s Choice) A171901

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 21228

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination with Pembrolizumab versus Docetaxel with or without Ramucirumab in Patients with Previously Treated Non-Small Cell Lung Cancer (Acclaim 2)

Disease Site: Lung, Non small cell lung cancer

View Trial Details

CLINICAL TRIAL 21257

A Phase 1 First-in-Human Study with ABBV-155 Alone and in Combination with Taxane Therapy in Adults with Relapsed and/or Refractory Solid Tumors

Disease Site: Breast, Lung

View Trial Details

CLINICAL TRIAL 21399

Phase I Study of MEM-288 Oncolytic Virus in Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 21534

Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 21712

A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naïve Subjects with Somatostatin Receptor Expressing Neuroendocrine Tumors

Disease Site: Any Site, Liver, Lung, Other Digestive Organ, Other Endocrine System, Pancreas, Rectum, Small Intestine, Stomach

View Trial Details

CLINICAL TRIAL 90005

Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 90007

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 90015

Phase 1 First-in-Human (FIH) Study of Leukocyte Immunoglobulin-Like Receptor B2 (LILRB2) Inhibitor Monoclonal Antibody (mAb) JTX-8064, as Monotherapy and in Combination with a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Disease Site: Breast, Lung, Melanoma, skin, Ovary, Pancreas, Urinary Bladder

View Trial Details

CLINICAL TRIAL 19622

Phase II Trial of Investigational Agents to Modulate Intermediate Endpoint Biomarkers, Including Pulmonary Nodules, in Former and Current Smokers

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 15768

Total Lung Care (TLC): Epidemiology of Lung Cancer

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 17723

Expansion of Enduring Infrastructure to Support Lung Cancer Screening Research

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 21184

Thoracic Program Trial Selection Protocol

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 21589

BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing

Disease Site: Breast, Colon, Esophagus, Lip, Oral Cavity and Pharynx, Lung, Ovary, Pancreas, Rectum, Stomach

View Trial Details

CLINICAL TRIAL 17971

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Disease Site: Lung

View Trial Details

CLINICAL TRIAL 20003

LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer(Lung-MAP Screening Study)

Disease Site: Lung, Non small cell lung cancer

View Trial Details